Antibody-based inhibitors of HIV infection

Bibliography

• CASADEVALL A, DADACHOVA E, PIROFSKI LA: Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. (2004) 2(9):695-703.
   PubMed Web of Science ®Google Scholar
• DESMAZES S, KAZATCHKINE MD, KAVERI SV: Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol. Sci. (2004) 25(6):306-310.
   PubMed Web of Science ®Google Scholar
• WU H, PFARR DS, TANG Y et al.: Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. (2005) 350(1):126-144.
   PubMed Web of Science ®Google Scholar
• DEZUBE BJ, PROPER J, ZHANG J et al.: A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a Phase I study. J. Infect. Dis. (2003) 187(3):500-503.
   PubMed Web of Science ®Google Scholar
• TRKOLA A, KUSTER H, RUSERT P et al.: Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. (2005) 11(6):615-622.
   PubMed Web of Science ®Google Scholar
• ARMBRUSTER C, STIEGLER GM, VCELAR BA et al.: Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J. Antimicrob. Chemother. (2004) 54(5):915-920.
   PubMed Web of Science ®Google Scholar
• SRIVASTAVA IK, ULMER JB, BARNETT SW: Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev. Vaccines (2004) 3(4 Suppl.):S33-S52.
   PubMedGoogle Scholar
• ZOLLA-PAZNER S: Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. (2004) 4(3):199-210.
   PubMed Web of Science ®Google Scholar
• MCCANN CM, SONG RJ, RUPRECHT RM: Antibodies: can they protect against HIV infection? Curr. Drug. Targets Infect. Disord. (2005) 5(2):95-111.
   PubMedGoogle Scholar
• SHEPPARD N, SATTENTAU Q: The prospects for vaccines against HIV-1: more than a field of long-term nonprogression? Expert. Rev. Mol. Med. (2005) 7(2):1-21.
   PubMedGoogle Scholar
• BURTON DR, DESROSIERS RC, DOMS RW et al.: HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. (2004) 5(3):233-236.
   PubMed Web of Science ®Google Scholar
• DIMITROV DS: Virus entry: molecular mechanisms and biomedical applications. Nat. Rev. Microbiol. (2004) 2(2):109-122.
   PubMed Web of Science ®Google Scholar
• WEI X, DECKER JM, WANG S et al.: Antibody neutralization and escape by HIV-1. Nature (2003) 422(6929):307-312.
   PubMed Web of Science ®Google Scholar
• ROBEN P, MOORE JP, THALI M et al.: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. (1994) 68(8):4821-4828.
   PubMed Web of Science ®Google Scholar
• BURTON DR, PYATI J, KODURI R et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 266(5187):1024-1027.
   PubMed Web of Science ®Google Scholar
• WYATT R, KWONG PD, DESJARDINS E et al.: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 393(6686):705-711.
   PubMed Web of Science ®Google Scholar
• ZHANG MY, SHU Y, PHOGAT S et al.: Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J. Immunol. Methods (2003) 283(1-2):17-25.
   PubMed Web of Science ®Google Scholar
• ZHANG MY, XIAO X, SIDOROV IA et al.: Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J. Virol. (2004) 78(17):9233-9242.
   PubMed Web of Science ®Google Scholar
• LABRIJN AF, POIGNARD P, RAJA A et al.: Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. (2003) 77(19):10557-10565.
   PubMed Web of Science ®Google Scholar
• MOULARD M, PHOGAT SK, SHU Y et al.: Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. USA (2002) 99(10):6913-6918.
   PubMed Web of Science ®Google Scholar
• TRKOLA A, PURTSCHER M, MUSTER T et al.: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. (1996) 70(2):1100-1108.
   PubMed Web of Science ®Google Scholar
• BURES R, MORRIS L, WILLIAMSON C et al.: Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J. Virol. (2002) 76(5):2233-2244.
   PubMed Web of Science ®Google Scholar
• GUNTHARD HF, GOWLAND PL, SCHUPBACH J et al.: A Phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. J. Infect Dis. (1994) 170(6):1384-1393.
   PubMed Web of Science ®Google Scholar
• CONLEY AJ, GORNY MK, KESSLER JA 2ND et al.: Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. (1994) 68(11):6994-7000.
   PubMed Web of Science ®Google Scholar
• GORNY MK, WILLIAMS C, VOLSKY B et al.: Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. (2002) 76(18):9035-9045.
   PubMed Web of Science ®Google Scholar
• STANFIELD RL, GORNY MK, WILLIAMS C, ZOLLA-PAZNER S, WILSON IA: Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure (Camb.) (2004) 12(2):193-204.
   PubMed Web of Science ®Google Scholar
• COTROPIA J, UGEN KE, KLIKS S et al.: A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1996) 12(3):221-232.
   PubMedGoogle Scholar
• CHOE H, LI W, WRIGHT PL et al.: Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell (2003) 114(2):161-170.
   PubMed Web of Science ®Google Scholar
• HUANG CC, VENTURI M, MAJEED S et al.: Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. USA (2004) 101(9):2706-2711.
   PubMed Web of Science ®Google Scholar
• CAVACINI LA, SAMORE MH, GAMBERTOGLIO J et al.: Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses (1998) 14(7):545-550.
   PubMed Web of Science ®Google Scholar
• STIEGLER G, ARMBRUSTER C, VCELAR B et al.: Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a Phase I evaluation. AIDS (2002) 16(15):2019-2025.
   PubMed Web of Science ®Google Scholar
• DEZUBE BJ, DOWEIKO JP, PROPER JA et al.: Monoclonal antibody hNM01 in HIV-infected patients: a Phase I study. J. Clin. Virol. (2004) 31(Suppl. 1):S45-S47.
   PubMed Web of Science ®Google Scholar
• MADDON PJ, LITTMAN DR, GODFREY M et al.: The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. Cell (1985) 42(1):93-104.
   PubMed Web of Science ®Google Scholar
• BURKLY L, MULREY N, BLUMENTHAL R, DIMITROV DS: Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies. J. Virol. (1995) 69(7):4267-4273.
   PubMed Web of Science ®Google Scholar
• KURITZKES DR, JACOBSON J, POWDERLY WG et al.: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. (2004) 189(2):286-291.
   PubMed Web of Science ®Google Scholar
• ROSSI D, ZLOTNIK A: The biology of chemokines and their receptors. Annu. Rev. Immunol. (2000) 18:217-242.
   PubMed Web of Science ®Google Scholar
• WU L, LAROSA G, KASSAM N et al.: Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. (1997) 186:1373-1381.
   PubMed Web of Science ®Google Scholar
• AARONS EJ, BEDDOWS S, WILLINGHAM T, WU L, KOUP RA: Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology (2001) 287(2):382-390.
   PubMed Web of Science ®Google Scholar
• KHURANA S, KENNEDY M, KING LR, GOLDING H: Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity. J. Virol. (2005) 79(11):6791-6800.
   PubMed Web of Science ®Google Scholar
• STEINBERGER P, SUTTON JK, RADER C, ELIA M, BARBAS CF 3RD: Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J. Biol. Chem. (2000) 275(46):36073-36078.
   PubMed Web of Science ®Google Scholar
• OLSON WC, RABUT GE, NAGASHIMA KA et al.: Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. (1999) 73(5):4145-4155.
   PubMed Web of Science ®Google Scholar
• CILLIERS T, NHLAPO J, COETZER M et al.: The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J. Virol. (2003) 77:4449-4456.
   PubMed Web of Science ®Google Scholar
• SHAHEEN F, COLLMAN RG: Co-receptor antagonists as HIV-1 entry inhibitors. Curr. Opin. Infect. Dis. (2004) 17(1):7-16.
   PubMed Web of Science ®Google Scholar
• ZHANG MY, SHU Y, RUDOLPH D et al.: Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J. Mol. Biol. (2004) 335(1):209-219.
   PubMed Web of Science ®Google Scholar
• DECKER JM, BIBOLLET-RUCHE F, WEI X et al.: Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. (2005) 201(9):1407-1419.
   PubMed Web of Science ®Google Scholar
• DEY B, DEL CASTILLO CS, BERGER EA: Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J. Virol. (2003) 77(5):2859-2865.
   PubMed Web of Science ®Google Scholar
• GERSHONI JM, DENISOVA G, RAVIV D, SMORODINSKY NI, BUYANER D: HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. FASEB J. (1993) 7(12):1185-1187.
   PubMed Web of Science ®Google Scholar
• MEYUHAS R, NOY H, MONTEFIORI DC et al.: HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1. Mol. Immunol. (2005) 42(9):1099-1109.
   PubMed Web of Science ®Google Scholar
• CAPON DJ, WARD RH: Antiviral effects of CD4 derivatives. Curr. Opin. Immunol. (1989) 2(3):433-438.
   PubMed Web of Science ®Google Scholar
• SCHOOLEY RT, MERIGAN TC, GAUT P et al.: Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A Phase I-II escalating dosage trial. Ann. Intern Med. (1990) 112(4):247-253.
   PubMed Web of Science ®Google Scholar
• CHAMOW SM, DULIEGE AM, AMMANN A et al.: CD4 immunoadhesins in anti-HIV therapy: new developments. Int. J. Cancer Suppl. (1992) 7:69-72.
   PubMedGoogle Scholar
• HODGES TL, KAHN JO, KAPLAN LD et al.: Phase I study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Antimicrob. Agents Chemother. (1991) 35(12):2580-2586.
   PubMed Web of Science ®Google Scholar
• ARTHOS J, CICALA C, STEENBEKE TD et al.: Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J. Biol. Chem. (2002) 277(13):11456-11464.
   PubMed Web of Science ®Google Scholar
• ALLAWAY GP, DAVIS-BRUNO KL, BEAUDRY GA et al.: Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses (1995) 11(5):533-539.
   PubMed Web of Science ®Google Scholar
• GAUDUIN MC, ALLAWAY GP, OLSON WC et al.: CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates. J. Virol. (1998) 72(4):3475-3478.
   PubMed Web of Science ®Google Scholar
• KETAS TJ, FRANK I, KLASSE PJ et al.: Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J. Virol. (2003) 77(4):2762-2767.
   PubMed Web of Science ®Google Scholar
• ZHU P, OLSON WC, ROUX KH: Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes. J. Virol. (2001) 75(14):6682-6686.
   PubMed Web of Science ®Google Scholar
• JACOBSON JM, ISRAEL RJ, LOWY I et al.: Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother. (2004) 48(2):423-429.
   PubMed Web of Science ®Google Scholar
• CASTAGNA A, BISWAS P, BERETTA A, LAZZARIN A: The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs (2005) 65(7):879-904.
   PubMed Web of Science ®Google Scholar
• VU JR, FOUTS T, BOB K et al.: An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro. AIDS Res. Hum. Retroviruses (2006) (In Press).
   PubMedGoogle Scholar
• CHALLITA-EID PM, KLIMATCHEVA E, DAY BT et al.: Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein. AIDS Res. Hum. Retroviruses (1998) 14(18):1617-1624.
   PubMed Web of Science ®Google Scholar
• ZHANG MY, SHU Y, SIDOROV I, DIMITROV DS: Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades. Antiviral Res. (2004) 61(3):161-164.
   PubMed Web of Science ®Google Scholar
• GORNY MK, MOORE JP, CONLEY AJ et al.: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. (1994) 68(12):8312-8320.
   PubMed Web of Science ®Google Scholar
• PARKER CE, DETERDING LJ, HAGER-BRAUN C et al.: Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J. Virol. (2001) 75(22):10906-10911.
   PubMed Web of Science ®Google Scholar
• ZWICK MB, LABRIJN AF, WANG M et al.: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. (2001) 75(22):10892-10905.
   PubMed Web of Science ®Google Scholar